Explore: Mitoxantrone

Mitoxantrone (INN, BAN, USAN; also known as Mitozantrone in Australia; trade name Novantrone) is an anthracenedione antineoplastic agent. Mitoxantrone

is an experimental antineoplastic (anti-cancer) drug, an analogue of mitoxantrone with fewer toxic effects on cardiac tissue. It acts as a topoisomerase

- an alkylating antineoplastic agent from the oxazafosforine group; Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that can intercalate

Uramustine Aclarubicin Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Pirarubicin Valrubicin Zorubicin Abraxane Cabazitaxel Docetaxel Larotaxel

often daunorubicin (can be substituted for doxorubicin or idarubicin or mitoxantrone). There were attempts to intensify the "7+3" regimen in order to try

sensitive to rituximab, fludarabine and mitoxantrone in monotherapies (e.g. multiple sclerosis). Fludarabine Plus Mitoxantrone With and Without Rituximab Versus

2011, mitoxantrone was the first medication approved for secondary progressive MS. In this population, tentative evidence supports mitoxantrone moderately

overall survival (OS) is markedly enhanced with cabazitaxel versus mitoxantrone after prior docetaxel treatment. FIRSTANA (ClinicalTrials.gov identifier:

abscess. It is usually lethal, but it has been found to be responsive to mitoxantrone and alemtuzumab, and it has also been responsive to autologous stem cell

are not anthracyclines include: Actinomycin-D Bleomycin Mitomycin-C Mitoxantrone Phototrexate Some antimetabolites can also be antibiotics, such as sulfanilamide